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Type 2 diabetes mellitus is a systemic disease characterized by intolerance to glucose and peripheral resistance to insulin. This
endocrine disease affects fundamental mechanisms of the central nervous system and jeopardizes the balance of vital functions
such as the cardiovascular and circadian rhythm. The increased prevalence of metabolic disorders in our society is aggravated
by endemic voluntary postponement of bedtime and by the current sedentary lifestyle, leading to epidemic proportions of obese
people. Diabetes and chronic loss of sleep share the fact that both affect millions and one is detrimental to the other. Indeed,
sleep deficits have marked modulatory effects on glucose metabolism and insulin sensitivity and foster metabolic syndrome that
culminates in sleep disorders like restless syndrome and sleep apnea, which in turn lead to poor sleep quality. We examine the
hypothesis that these two worldwide emerging disorders are due to two interlinked cycles. In our paradigm, we establish an
intimate relationship between diabetes and sleep disturbances and postulate possible mechanisms that provide support for this
conjecture. In addition, we propose some perspectives about the development of the reciprocal interaction between predictor
components of metabolic syndrome and sleep disturbances that lead to poor sleep quality. The ability to predict the development
and identify or associate a given mode of sleep disturbance to diabetes would be a valuable asset in the assessment of both.
Furthermore, major advances in care coupled with healthy lifestyles can ensure a higher quality of life for people with diabetes.
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Introduction
In the past 50 years there has been a substantial
increase in lifespan for most populations. This may be
attributed chiefly to epidemiological control of infectious
diseases and advances in modern medicine. Consequently,
a number of non-infectious chronic pathologies that were
previously almost non-existent are now ubiquitous, with a
major impact in economic and social terms. In both devel-
oped and developing countries there is an epidemiologic
trend in which metabolic disorders have been recognized
as a serious issue. Of the various metabolic diseases, type
2 diabetes mellitus was fairly rare at the beginning of the
20th century but has become a major hurdle for health care
worldwide, and is likely to remain so. The estimated preva-
lence of diabetes was 2.8% of the population in 2000,
directly affecting 177 million individuals worldwide, a figure
almost 5-fold the estimates of 10 years ago. By 2030, an
estimated 4.4% of the world’s population will be afflicted,
corresponding to 370 million diabetics (1). Indeed, while
the human and economic costs of diabetes are difficult to
calculate, the total medical costs incurred annually in the
US alone are close to US$100 billion.
The majority of type 2 diabetes cases are preventable.
Although there is evidence that a genetic predisposition is
important in the development of this disease, the rapid
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increase in prevalence in the world shows that environ-
mental factors, such as overweight and a sedentary lifestyle,
are of major importance (2). Type 2 diabetes in particular
may go unnoticed for years, since the early symptoms are
typically mild and sporadic. However, this endocrine dis-
ease has been prominent for its deleterious effects in
undermining various organic systems and its widespread
occurrence. Diabetes promotes devastating micro- and
macrovascular complications that impose an enormous
strain on health care systems worldwide. The literature has
documented the impact of diabetes on various organs of
the body, which leads to several central nervous system
alterations involving neurobehavioral and neurotransmit-
ter problems, autonomic dysfunction, adversely affected
endocrine function (3), and sleep disturbances (4,5).
Associated with the endemic condition of diabetes in our
society, chronic sleep loss is increasingly common in indus-
trialized societies and affects about 45% of all adults (6).
Furthermore, alterations in only one of these systems can
gradually lead to marked deregulation of the other. In this
respect, intriguingly, a dramatic increase in the incidence of
obesity and diabetes seems to develop at the same time as
self-reported sleep duration decreases, and this may indi-
cate a close relationship between the two (7,8).
Sleep is a complex behavioral state that occupies one-
third of the human life span. Although viewed as a passive
condition, sleep is a highly active and dynamic process.
Until recently, it was believed that sleep was important
primarily for restoring brain functions. However, there is
increasing evidence that sleep also modulates the meta-
bolic, endocrine and cardiovascular systems (9).
Indeed, a recent study observed a consistent differ-
ence between diabetic subjects and non-diabetic subjects
in the number of disturbances per hour of sleep, indicating
a possible influence of diabetes on the sleep pattern (10).
The clinical and public health significance of linking sleep-
related abnormalities to abnormal glucose metabolism is
of paramount significance and thus an accurate and suc-
cinct summary of the available evidence is invaluable.
Thus, the aim of this review was to select the most
relevant and representative articles that have associated
sleep disturbances with diabetes and to propose some
perspectives about the development of the reciprocal in-
teraction of these two emerging worldwide disorders.
Metabolic syndrome
There is increasing evidence that metabolic syndrome
is an important risk factor for the onset of type 2 diabetes
(11). In this respect, the odds for individuals with metabolic
syndrome to develop diabetes are 5-fold higher than for
normal people. Two are the features that appear to stand
out as potential causative factors: resistance to insulin and
abnormal fat distribution (central obesity). Yet other factors
have also been implicated in the development of this
syndrome including impaired tolerance to glucose, hyper-
tension and disorders of lipid metabolism. Metabolic syn-
drome genesis occurs after prolonged exposure to a se-
ries of insidious factors that may originate either from a
complex chain of genetic factors or from an unhealthy
lifestyle, essentially affecting older individuals (12).
Metabolic syndrome is very common, affecting about
44% of the United States population over the age of 50
years (13). Among older individuals (≥50 years old) in the
United States, 17% have diabetes and 86% of these
patients suffer from metabolic syndrome (13). The progress
in understanding the metabolic staging of diabetes over
the past few years has led to significant advances in the
regimen of treatment of this devastating disease. Improve-
ments in the treatment or prevention of the disease will
depend on understanding the underlying molecular patho-
physiology in more detail.
The high prevalence of metabolic syndrome has impor-
tant health implications. Visceral fat accumulation observed
in the obese leads to dysfunction of adipocytes. Adipose
cells are responsible for the synthesis of innumerable
proteins that act systemically, dubbed adipocytokines.
Except for adiponectin, which prevents cardiovascular dis-
eases as well as metabolic diseases, including type 2
diabetes, adipocytokines are responsible for the chronic
inflammatory process that precedes insulin resistance and
plays a fundamental role in the physiopathological mech-
anisms that lead to obesity in type 2 diabetes.
Leptin is the main peptide produced by adipocytes and
its serum concentration represents an important peripher-
al signal in the regulation of food intake and energy expen-
diture. Leptin suppresses food intake and increases en-
ergy expenditure, with its serum levels decreasing in the
fasting state and increasing after eating (14). Unlike adipo-
nectin, the association of serum leptin concentrations with
serum lipids has been inconsistent (15). Its concentration
is increased in obese subjects in parallel with fat accumu-
lation (16). Leptin is associated more with subcutaneous
than visceral adipose tissue (17). Moreover, leptin concen-
trations have been closely correlated with alterations in
lipoproteins (VLDL and HDL) typically found in insulin-
resistance states (18).
Implications of metabolic impairments in
sleep
A consistent difference between diabetic and non-
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diabetic subjects in the incidence of sleep disturbances
(especially respiratory disturbances) per hour of sleep has
been reported (10) (Table 1). Insulin-dependent diabetes
mellitus can lead to an overall depression of ventilatory
control mechanisms (19). Indeed, several studies have
shown a strong association of obstructive sleep apnea
syndrome (OSAS) with obesity, male gender (android-
central obesity), post-menopausal women, hypertension
and diabetes, factors associated with metabolic syndrome
(20-25). Based on the fact that excessive daytime sleepi-
ness and fatigue are critical symptoms of sleep apnea and
frequent complaints of obese people, an important study
concluded that this sleep disturbance is a morbid charac-
teristic of obese patients which might be related to meta-
bolic/circadian abnormality of the disorder (26). Studies
have clearly shown that type 2 diabetic patients sleep less
than the population in general (4,5). Moreover, restless
syndrome is frequently found in diabetic patients leading
to poor sleep quality (27). In this respect, a gradual decrease
in self-reported sleep duration seems to have developed
over the same period as the dramatic increase in the inci-
dence of obesity and diabetes, indicating a close relation-
ship between sleep cycle and diabetes (7,8) (Table 1).
Finally, a recent study demonstrated that 7 h of exer-
cise a week significantly reduced the number of apnea
events per night of sleep, regardless of body mass index,
age or gender (28). Given the effects of physical exercise
on insulin resistance and visceral adiposity, verified by
weight control, it is possible to speculate that the favorable
effect of exercise on sleep apnea occurs through the
correction of metabolic abnormalities.
Obesity
The International Diabetes Federation considers obe-
sity to be one of the main drivers of the high prevalence of
metabolic syndrome, contributing to hyperglycemia and
insulin resistance. This is where a striking association
between obesity with type 2 diabetes mellitus can be
demonstrated (29).
Obesity should be addressed as both a disease and a
lifestyle issue. A majority of individuals suffering from type
2 diabetes are obese, with central visceral adiposity, and
an imbalance in energy intake and expenditure that leads
to numerous metabolic abnormalities (30). Insulin resis-
tance might be the result of obesity, but might also contri-
bute to its development. Recent insights into the biology of
the adipocyte as an endocrine organ have supported this
latter idea.
Feeding behavior depends on the integration of meta-
Table 1. Implications of metabolic impairments in sleep and their prevalence in specific population groups.
Metabolic disorders Sleep disturbances Sample Age (years) Gender References
Diabetes 33.7% OSAS (diabetics) 184 diabetics 32-57 M/F 47
8.2% OSAS (controls) 99 controls
Obesity 40% men with OSAS 200 obese women 16-72 M/F 32
3% women with OSAS 50 obese men
Control 128 controls (80 F/48 M)
Polycystic ovary 30 times more likely to suffer 53 premenopausal women 16-45 F 26
syndrome from sleep-disordered breathing
54% obese 40-60% OSAS 150 healthy mildly obese 58-67 M 37
46% overweight
40% glucose intolerance
13.3% diabetes
High body mass index, Increased stages 1 and 2 of 468 diabetics 61-74 M/F 10
central obesity, large neck sleep
circumference Decreased REM, stages 3 and
4 of sleep
Twice increased apnea
Diabetes 16% sleep loss 50 diabetics 45-65 M 53
OSAS = obstructive sleep apnea syndrome; REM = rapid eye movements; M = male; F = female.
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bolic, autonomic, endocrine, and environmental factors
coordinated with an appropriate state of cortical arousal
(wakefulness). Thus, this behavior is critically dependent
on appropriate sleep-wakefulness cycling. Indeed, co-
morbid disturbances of sleep, appetite, and metabolism
are well-described symptoms of obesity (31).
Obesity is the strongest and probably most relevant
risk factor for sleep disordered breathing (especially OSAS).
The mechanisms underlying the effects of obesity on the
risk of OSAS may be related to fat deposition in airway
anatomy or alterations in upper airway function.
Significant sleep apnea is present in 40% of obese
individuals, and 70% of OSAS patients are obese (32). Not
only increased body weight but also fat distribution plays a
major role in the development of OSAS. Of all the anthro-
pometric variables, studies suggest that central obesity
rather than more generalized distribution of body fat is an
important risk factor for OSAS in obese subjects (4,33). A
significantly greater amount of visceral fat, resulting from
the action of insulin, may be observed in sleep apneic
subjects compared with obese controls (33).
Insulin resistance
The hypothesis that visceral obesity, insulin resistance
and environmental factors are the principal culprits that
progressively lead to worsening of metabolic syndrome
and sleep disturbances has recently gained much accep-
tance (34). Progressive deterioration of the sleep cycle
may then accelerate the worsening of visceral obesity and
of metabolic syndrome by providing a stress stimulus and
causing nocturnal elevations of hormones, such as cortisol
and insulin, that promote visceral adiposity, metabolic
abnormalities and cardiovascular complications (35).
It is well known that insulin sensitivity decreases with
advancing age and is closely correlated with increased
body fat. After years of obesity, persistent resistance to
glucose uptake (despite the compensatory mechanism of
elevated glycemia and insulinemia) gradually leads to type
2 diabetes mellitus and the pathogenesis of metabolic
syndrome.
Despite the evident relationship between obesity and
insulin, a relevant study demonstrated that OSAS and
insulin resistance were present even in non-obese sub-
jects (36). In recent decades, OSAS has emerged as a
heavily researched topic, especially in view of its clinical
consequences. Punjabi and co-workers (37) reported in-
sulin resistance even in mild forms of sleep apnea.
To determine whether pathogenic mechanisms of sleep
apnea were observed in disorders in which insulin resis-
tance is a primary abnormality, Vgontzas and co-workers
(38) investigated if this sleep disorder was present in
women with polycystic ovary syndrome. They found that
polycystic ovary syndrome women were 30 times more
likely to suffer from sleep disordered breathing than con-
trols. The data suggest that, in fact, insulin resistance is
probably a primary factor involved in the pathogenesis of
OSAS.
Influence of sleep disturbances on the onset
of diabetes
There are bidirectional interactions between sleep and
the endocrine system. Several hormones have the capac-
ity to affect sleep but recent research has started to de-
scribe sleep as the key factor in physiological restitution,
with far-reaching medical implications.
The sleep cycle is closely related to endocrine and
metabolic function and to sympathovagal balance, with
sleep deprivation being detrimental to these systems (Fig-
ure 1). Therefore, although the primary function of sleep
may be cerebral restoration, sleep debt also has conse-
quences for peripheral function, that, if maintained chroni-
cally, could have an impact on carbohydrate metabolism
and endocrine function, including decreased glucose tol-
erance and insulin sensitivity (8). These effects are similar
to those seen in normal ageing and, therefore, it would not
be unreasonable to raise the hypothesis that sleep debt
increases the severity of age-related chronic disorders
(39) such as type 2 diabetes.
Various epidemiological studies have been conducted
in order to determine the relationship between sleep and
the incidence of diabetes (Table 2). West and colleagues
Figure 1. Potential interrelationships between sleep distur-
bances, glucose metabolism, obesity, and diabetes.
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(40), investigating a hospital-based population of 1600
men, reported prevalence of OSAS among 31% of patients
with high risk of developing diabetes and 13% among the
low risk patients. Another investigation demonstrated that
sleep disturbances may contribute to the development of
insulin resistance and type 2 diabetes either directly, by
their deleterious effect on glucose regulation components,
or indirectly, by deregulating appetite, leading to weight
gain and obesity, a major risk factor for insulin resistance
and diabetes (41). Studies have demonstrated that sleep-
disordered breathing is associated with cardiovascular
complications, including alterations in systemic blood pres-
sure (42,43). Multiple mechanisms have been proposed to
link sleep-disordered breathing with cardiovascular dis-
ease: increased sympathetic activity, endothelial dysfunc-
tion, and metabolic dysregulation (44). Therefore, although
the primary function of sleep may be restoring brain func-
tions, and in view of the evidence that sleep modulates
metabolic and endocrine regulation (45), sleep distur-
bances may very well have long-term adverse effects on
health (39).
Sleep loss
Chronic sleep loss is increasingly common in industri-
alized societies, affecting about 45% of adults (6). Normal
average sleep duration has decreased from 8.0-8.9 h per
night in 1960 (46) to about 6.9-7.0 h in 2000-2002. This
sleep impairment may result from various common sleep
disturbances, such as insomnia and OSAS and may lead
to striking alterations in metabolic and endocrine functions
(39). Furthermore, long-term sleep loss may represent a
novel risk factor for weight gain, insulin resistance, and
type 2 diabetes.
A recent prospective study on women has indicated an
interesting association between sleep patterns and later-
onset type 2 diabetes mellitus. It was observed that a
greater incidence among both short-term (<6 h) and long-
term (>8 h) sleepers (34), as well as sleep loss, have been
related to glucose tolerance and to increased risk of type 2
diabetes (47,48).
An important factor that may contribute to the patho-
genesis of type 2 diabetes is the higher plasma concentra-
tions of interleukin-6 (IL-6) and tumor necrosis factor-α
(TNF-α) regardless of obesity or insulin resistance (4,49).
These inflammatory cytokines play an important role in
mediating peripheral insulin resistance by inhibiting glu-
cose uptake by fat and muscle tissue, increasing the
concentrations of counter-regulatory hormones, and in-
ducing the release of free fatty acids via stimulation of
Table 2. Effects of sleep disturbances on the onset of predictor components of diabetes.
Sleep disturbances Metabolic disorders Sample Age (years) Gender References
Sleep restriction Glucose tolerance decreased 40% 11 normal men 18-27 M 39
Insulin response decreased 30%
Apneics: High body mass index, central obesity, 14 OSAS 38-49 M 4
decreased total insulin resistance, glucose tolerance 11 obese
sleep time, stage 2 12 controls
and REM sleep
Sleep loss Insulin response decreased 40% in 13 short sleepers 23-42 M/F 5
short sleepers 14 normal sleepers
OSAS 10% diabetes 81 apneics 27-75 M 18
6% glucose intolerance
40% obesity
47% overweight
80% OSAS Apneics: high body mass index, central 197 possible sleep 42-52 M 36
obesity, large neck circumference, apneics
glucose intolerance, insulin resistance
4.3% short sleepers Increased risk for diabetes (short and 70,026 30-55 F 34
4.5% long sleepers long sleepers)
11.5% snoring (long sleepers)
M = male; F = female; REM = rapid eye movements; OSAS = obstructive sleep apnea syndrome.
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lipolysis (50). A recent study has demonstrated that a
restriction of sleep of 2 h/night for 1 week in young healthy
men and women is associated with a significant increase in
sleepiness, decrements in psychomotor performance, and
increased secretion of the proinflammatory cytokines IL-6
and TNF-α (51).
Additionally, sleep restriction is associated with reduc-
tions in leptin (the appetite suppressant), elevations in
ghrelin (the appetite stimulant) and increased appetite,
especially for foods with high carbohydrate contents (47).
Sleep loss, therefore, seems to alter the ability of leptin and
ghrelin to accurately signal caloric needs and could lead to
excessive caloric intake when food is freely available (47).
Evidence suggests a possible role for chronic sleep loss in
the current epidemic of obesity (47).
One study found that short-duration or partial sleep
deprivation (4 h of sleep per night for 6 nights), experi-
enced by 11 young men triggered impaired glucose toler-
ance, higher secretion of evening cortisol concentrations,
increased sympathetic nervous system activity, and re-
duced leptin secretion (39). Another study reported that a
one-week period of sleep restriction (4 h of sleep) in young,
healthy subjects could produce a prediabetic state (8).
Although long-term sleep loss is often secondary to
somatic or psychiatric illness, it appears that insomnia may
play a more central role in the pathogenesis of somatic
illness and metabolic dysregulation (52). An association
between sleep duration and increased risk of developing
diabetes has been reported by researchers, who also
offered a number of speculative explanations (53). One
hypothesis was that excessive sleep per se could directly
lead to an increased risk of diabetes. Another is that long
sleep duration may be an early symptom of diabetes,
possibly predating its official diagnosis (34). There is the
need for further research to better elucidate the biological
mechanism underlying this association, and to determine
whether the etiology of habitually short sleep time affects
long-term health (34).
Obstructive sleep apnea syndrome
Sleep apnea is a chronic condition characterized by a
heterogeneous group of disorders including reduction or
complete cessation of airflow during sleep, associated with
impairment of daytime functions. At least 2-4% of the gen-
eral population may be affected and there are much higher
estimates based on demographic variables such as age,
gender, and body mass index (54). A marked association
may be observed between obesity, snoring and sleep ap-
nea, and it has been found that heavy snoring is both a major
manifestation and predictor of OSAS (55). Among morbidly
obese patients with sleep apnea and type 2 diabetes, nasal
continuous positive airway pressure treatment for 4 months
improved insulin responsiveness (41).
A human study has shown that individuals acutely
exposed to hypoxia, either in a high-altitude setting (56) or
in the context of an experimental paradigm (57), present
reduced glucose tolerance with a concomitant increase in
circulating concentrations of adrenaline. An important point
here, however, is that exposure to sustained hypoxia (at
high altitudes, for example) is not associated with persist-
ent abnormalities in glucose homeostasis (57).
Obstructive episodes may lead to a number of acute
pathophysiological consequences including intermittent
hypoxia, severe sleep fragmentation, and activation of the
sympathetic nervous system. Each episode of hypoxemia,
with larger desaturations, is accompanied by transient
periods of sympathoexcitation that can influence glucose
homeostasis by increasing glycogen breakdown and glu-
coneogenesis (58). Furthermore, autonomic activation in
sleep apneics may also increase corticotropin-releasing
hormone, cortisol production and inflammatory cytokines
(IL-6 and TNF-α) (52). Vgontzas and co-workers (38) have
shown that obese persons with sleep apnea have higher
IL-6 concentrations than obese persons without sleep
apnea. In that study, the investigators also suggested that
IL-6 production by adipocytes might contribute to chronic
low-level systemic inflammation in obese persons (38).
Furthermore, given that TNF-α is thought to modulate
somnolence and fatigue, this cytokine may have a role in
mediating the constitutional symptoms of OSAS (59).
In summary, the effects of increased sympathetic activ-
ity, alterations in glucocorticoid homeostasis, and the ef-
fects of intermittent hypoxia may contribute to the develop-
ment of glucose intolerance and insulin resistance in sleep
disordered breathing (60). Furthermore, these episodes of
respiratory disturbance may induce frequent arousal epi-
sodes and the consequent sleep loss may also facilitate
the development of metabolic disturbances (39).
Literature search strategy
In this systematic review, we identified reports using a
Medline search through the PubMed database (1978-
2007) by combining the key words sleep and apnea with
diabetes, metabolic syndrome, obesity, and insulin resis-
tance. We searched citation lists in retrieved papers to
identify additional references. Papers were selected on
the basis of the best available evidence for each specific
question discussed. Only English language papers were
included.
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